References
- WHO. Human challenge trials for vaccine development: regulatory considerations 2016 [Feb 20, 2021]. Available from: https://www.who.int/biologicals/expert_committee/Human_challenge_Trials_IK_final.pdf.
- US: CHALLENGE TRIALS FOR COVID-19 2020 [Feb 20, 2021]. Available from: https://www.1daysooner.org/us-open-letter.
- UK government signs contract for COVID-19 challenge trial 2020 [Feb 20, 2021]. Available from: https://pharmaphorum.com/news/uk-government-signs-contract-for-covid-19-challenge-trial/.
- World’s first coronavirus Human Challenge study receives ethics approval in the UK 2021 [Feb 20, 2021]. Available from: https://www.gov.uk/government/news/worlds-first-coronavirus-human-challenge-study-receives-ethics-approval-in-the-uk.
- Kahn JP, Henry LM, Mastroianni AC, et al. Opinion: for now, it’s unethical to use human challenge studies for SARS-CoV-2 vaccine development. Proc Natl Acad Sci U S A. 2020. https://doi.org/https://doi.org/10.1073/pnas.2021189117
- South Africa suspends Oxford/AstraZeneca COVID vaccine roll-out 2021 [Feb 20, 2021]. Available from: https://www.aljazeera.com/news/2021/2/7/south-africa-suspends-astrazeneca-vaccine-rollout.
- WHO. Feasibility, potential value and limitations of establishing a closely monitored challenge model of experimental COVID-19 infection and illness in healthy young adult volunteers 2020. Available from: https://www.who.int/publications/m/item/feasibility-potential-value-and-limitations-of-establishing-a-closely-monitored-challenge-model-of-experimental-covid-19-infection-and-illness-in-healthy-young-adult-volunteers.
- Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020 Jun;20(6):669–677.
- Plotkin SA, Caplan A. Extraordinary diseases require extraordinary solutions. Vaccine. 2020 May 19;38(24):3987–3988.
- CDC. Emerging SARS-CoV-2 Variants. 2020 [Feb 20, 2021]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html.
- Deming ME, Michael NL, Robb M, et al. Accelerating development of SARS-CoV-2 vaccines – the role for controlled human infection models. N Engl J Med. 2020 Sep 3;383(10):e63.
- Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 Jul 3;369(6499):77–81.
- OncoImmune’s SACCOVID™ (CD24Fc) exhibits superb therapeutic efficacy – a potential breakthrough in treating severe and critical COVID-19 2021 [Feb 20, 2021]. Available from: https://www.biospace.com/article/releases/oncoimmune-s-saccovid-cd24fc-exhibits-superb-therapeutic-efficacy-a-potential-breakthrough-in-treating-severe-and-critical-covid-19/.
- Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021. https://doi.org/https://doi.org/10.1038/s41586-021-03291-y